They cited the recommendation by the FDA as their motivating factor, who qualified cannabis as having no medical value.
The FDA detailed three reasons why cannabis should not be rescheduled; the first is a high potential for abuse and addiction, the second is a lack of accepted medical use, and finally the lack of safety information.
The FDA uses a five-part litmus test to gauge the medical value of a chemical including “the drug’s chemistry must be known and reproducible,” “there must be adequate safety studies,” “there must be adequate and well-controlled studies proving efficacy,” “the drug must be accepted by qualified experts,” and “the scientific evidence must be widely available.”
The FDA has high standards when it comes to acceptable research, which is a good thing for our overall health as a nation. However, due to the difficulty of conducting randomized, double-blind, placebo-controlled clinical studies on cannabis the FDA could only find 11 studies which met their standards.
There seems to be an acknowledgement of the rough road to study cannabis by the DEA in their promotion to allow more locations to cultivate medical cannabis for government approved research programs.
In the history of our country, University of Mississippi has been the one and only location to legally grow cannabis for the government.
How’s that for a bottleneck!
Let’s try to see the glass half full, and appreciate that while the DEA says no to rescheduling, they are paving a wider road to medical cannabis research.